TransCon PTH Granted Orphan Drug Designation in Europe
The European Commission (EC) has granted orphan drug designation to Ascendis Pharma’s experimental hormone replacement therapy TransCon PTH, currently in development for the treatment of hypoparathyroidism. Medicines…